RBGLY

Reckitt Benckiser Group PLC ADR

RBGLY, USA

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under Airborne, Movefree, and neuriva names; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.

https://www.reckitt.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RBGLY
stock
RBGLY

Reckitt Benckiser Group (OTCMKTS:RBGLY) Sees Strong Trading Volume - Here's What Happened MarketBeat

Read more →
RBGLY
stock
RBGLY

RECKITT BCKR ADR To Carry Out 24-for-25 Reverse Stock Split On February 2nd, 2026 富途资讯

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

2

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

33.16

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

9.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Medium

15.18 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

3.89 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Medium

9.37 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.89

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Reckitt Benckiser Group PLC ADR

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(4)
Dividend
Decent Dividend Payer(5)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(6)
Growth
Moderate Growth(5.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(6.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.